Physician profile
Melissa J Ferrari
NPI 1477893741
$222,935.26
in general payments reported to CMS, 2019-2025
31 companies · $152K in 2025
The $152K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $5,043 · 2023: $16K · 2024: $50K · 2025: $152K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $43K · Food and Beverage: $14K · Consulting Fee: $9,867 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,633.50 |
| Travel and Lodging | $42,532.70 |
| Food and Beverage | $13,986.16 |
| Consulting Fee | $9,867.00 |
| Education | $160.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $146,004.18 | 2021-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $55,496.97 | 2021-2025 | |
| Lilly USA, LLC | $8,334.99 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $2,010.95 | 2021-2022 | |
| Pfizer INC. | $1,819.01 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,762.30 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $1,761.04 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $1,748.77 | 2024-2025 | Tremfya, Stelara |
| Celltrion USA INC. | $746.11 | 2025 | Zymfentra, Vegzelma |
| Merck Sharp & Dohme LLC | $670.95 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $467.08 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $336.64 | 2024-2025 | Voquezna |
| Genzyme Corporation | $298.57 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $274.51 | 2022-2025 | Ocaliva |
| Gilead Sciences, INC. | $254.28 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $253.60 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $174.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $122.64 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $63.31 | 2021-2025 | Sucraid |
| Redhill Biopharma INC. | $54.18 | 2021-2024 | Talicia |
| Vivus LLC | $43.57 | 2022-2024 | Qsymia |
| Ironwood Pharmaceuticals, INC | $36.66 | 2024 | |
| Ferring Pharmaceuticals INC. | $35.20 | 2024 | Rebyota |
| Alnylam Pharmaceuticals INC. | $25.86 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $23.70 | 2025 | Zenpep |
| Blueprint Medicines Corporation | $21.95 | 2023 | |
| Eisai INC. | $19.21 | 2024 | |
| Evoke Pharma, INC. | $18.76 | 2024 | |
| Novo Nordisk INC | $18.47 | 2025 | Wegovy |
| Exact Sciences Corporation | $12.76 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Ferrari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.